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The temporal and spatial deposition of extracellular matrix
proteins is critical for nephrogenesis and glomerular
maturation. We previously characterized leprecan as a novel
chondroitin sulfate proteoglycan which has been recently
shown to have prolyl hydroxylase activity. In this study, we
examine the distribution of leprecan during nephrogenesis
and after a hypertrophic stimulus to the adult kidney. During
development, leprecan was localized to mesenchymal
aggregates, early comma- and S-phase structures as
determined by immunohistochemistry and in situ
hybridization. Leprecan mRNA was increased in cells around
the vascular cleft of the S- and comma-phase glomeruli.
Expression was found in podocytes, mesangial cells, and
parietal epithelial cells of loop-phase glomeruli. Leprecan
mRNA was substantially decreased in the glomeruli of the
adult kidney compared to the developing kidney with
a uniform distribution between the glomeruli and the
tubules. Within adult glomeruli, leprecan was found in the
mesangium mesangial matrix, podocytes, and in Bowman’s
capsule. In response to glomerular hypertrophy, produced
by unilateral nephrectomy, leprecan synthesis was increased
in the adult kidney. We suggest that the regulated expression
of leprecan during glomerular development or hypertrophy
coupled with its reported prolyl hydroxylase activity plays a
role during basement membrane assembly.
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Basement membranes are pericellular matrices that underlie
epithelial cells and surround muscle nerve and fat cells.
Martin et al.1 proposed the term ‘matrisome’ to describe
the relationship between structural proteins that were
solely thought to comprise basement membranes: laminin,
heparan sulfate proteoglycan, entactin/nidogen, and type IV
collagen. Since then, basement membrane research has
greatly expanded the number of molecules commonly
associated with basement membranes to include numerous
isoforms of the basic structural elements, matricellular
proteins, growth factors, and cytokines.
Previously, we reported the characterization of a novel
basement membrane-associated chondroitin sulfate proteo-
glycan, leprecan,2 secreted by L-2 cells, a parietal endo-
derm cell line.3 In that study, we identified four leprecan
family members which included unknown protein B
(accession number U47926), CASP (accession number
X97607), No55 (accession number Q92791), and SC65
(accession number X65454). Since its initial characterization,
the leprecan family has expanded to include leprel1 (acces-
sion number NM018192) and leprel 2 (accession number
NM014262).4 All members share homology in the CXXXC
repeat/tetratricopeptide repeat region of leprecan occurring
in the amino end of the molecule (Figure 1a). No55 and SC65
are unique in the leprecan family in that they lack a signal
peptide and hence are solely intracellular in their distribution
and function. The subsequent prediction of the presence
of a 2-oxoglutarate, Fe(II)-dependent oxygenase domain by
Aravind and Koonin5 using sequence profile searches led to
the identification of a domain in the carboxyl half of leprecan
as having prolyl hydroxylase (PH) activity4,6 (Figure 1a),
which suggested that one aspect of leprecan, leprel1, and
leprel2 biology may be involved with the assembly of
collagens. CASP, No55, and SC65 lack the PH region, and
represent truncated leprecan family members. Leprecan can
also exist in a truncated variant formed at the mRNA level by
alternative splicing.4,7
In our previous study,2 using a polyclonal antiserum
(Rb2096) directed against a fusion protein representing
R403-L728 of the leprecan protein (Figure 1a), we showed
that in the kidney leprecan was present in the glomerular
basement membrane, mesangial matrix, and Bowman’s
capsule of the nephron. In addition, Rb2096 immunostained
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renal tubular basement membranes and the outer capsule of
the kidney. Given the fact that two additional leprecan family
members exist that have a high homology with leprecan in
the R403-L728 region of the molecule,4 one would predict
that the Rb2096 antiserum would have a high degree of
cross-reactivity with leprel1 and leprel2 and might not
discern between the family members that bear the PH
domain. To study the distribution of leprecan during renal
development, a new polyclonal serum was developed against
a peptide representing a region near the amino terminus of
leprecan that is not highly homologous with its respective
family members. Using this newly developed polyclonal
antiserum and in situ hybridization, in this study, we examine
the distribution of leprecan in the developing kidney, the
normal adult kidney, and in the kidneys of unilateral
nephrectomized animals.
RESULTS
The original polyclonal antiserum, Rb2096, targeted a fusion
protein (R403-L728) that approximated the carboxyl half of
the leprecan molecule (Figure 1). The rationale for choosing
that region of leprecan at that time was to avoid potential
cross-reactivity with other known leprecan family members
No55, SC55, and CASP/Dualin, whose sequence homology
with leprecan is highly conserved at the amino-terminal
portion of the molecule (W40-E430).2 With recent reports
of two other leprecan family members, leprel1 and leprel
2,4 which share homologies along the full length of leprecan,
it became important to develop a new antiserum that
would have optimal reactivity for leprecan. Therefore, the
peptide T71ELPWAPDLDLGPASSLNHDPGAAALHD98 from
a region near the amino-terminal end of leprecan was
identified as having minimal homology to other family
members. This peptide (Figure 1a and b) was used to develop
a new polyclonal antiserum, Rb6480. Initial characterization
of Rb6480 antiserum by ELISA using the above peptide as the
target showed that Rb6480 had high-specific activity against
the peptide, the original antiserum, Rb2096 did not recognize
the peptide (Figure 2). Rb6480 was further characterized
by Western immunoblot assay (Figure 2) in which the
fusion protein M1-Q399 was electrophoretically transferred
to nitrocellulose after SDS–PAGE. The immunoblot showed
that Rb6480 recognized the target sequence embedded within
M1-Q399 fusion protein.
Leprecan distribution in the adult kidney
One of the limitations of the Rb2096 antiserum was that it
only immunostained frozen tissue sections. In kidney
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Figure 1 | Basic organization of the leprecan core protein. (a) A cartoon that shows the domain organization of the leprecan core
protein. Leprecan is tentatively a bifunctional molecule, with a PH domain at the carboxyl end of the molecule. A leucine zipper motif is
adjacent to the PH domain and may function in dimerization. At the amino end are four tetratricopeptide motifs (TPR) that may impart
a protein docking function to the amino end of the molecule. There are also four CXXXC motifs present at the amino end of the molecule,
four glycosaminoglycan acceptor sites, one RGD motif, and four N-glycosylation sites present in the molecule. The location of the recognition
region for Rb6480 (short black bar) and Rb2096 (long black bar) are indicated above the protein construct. The mRNA probe was
developed from a region of mRNA that encodes a portion of the protein shown indicated by the appropriate bar. (b) The alignment of
a portion of leprecan and its homologous family members – the dark shaded boxes indicate regions of homology. The black bar above
the sequence shows the region of the protein that was used to develop the Rb6480 antiserum. (c) Is the exon organization of the leprecan
gene superimposed above the leprecan cDNA sequence. The leprecan mRNA probe spans exons 9–11.
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sections immunostained with Rb2096, leprecan-associated
immunofluorescence was found in the mesangial matrix,
glomerular basement membrane, Bowman’s capsule, tubular
basement membranes, and in the renal capsule.2 Rb2096 also
stained in a diffuse pattern of intracellular localization that
was obscured owing to the thickness of the frozen sections.
To clarify better the immunolocalization of leprecan, frozen
tissue sections (Figure 3a–d) were double-label immuno-
stained with a monoclonal antibody directed against
basement membrane chondroitin sulfate proteoglycan
(BM-CSPG)8 and Rb2096. The resultant images were processed
using a digital deconvolution algorithm to substantially
decrease the contribution of fluorescence signal that origi-
nated from above and below the focal plane of the image. In
deconvolved images, leprecan-associated immunostaining
overlapped the mesangial matrix-associated BM-CSPG pat-
tern of immunofluorescence. However, the appearance of
leprecan staining was punctate (Figure 3d) rather than the
fibrillar pattern for BM-CSPG (Figure 3c) in these sections.
Given the former observation that Rb2096 may have
potential cross-reactivity for other prolyl 3-hydroxylase
(P3H)-containing members of the leprecan family and could
show a differential staining pattern from that seen for
Rb6480, serial frozen sections of rat kidney were immuno-
stained separately with each antibody, and the slides imaged
as described above. Both antisera showed a similar pattern
of localization within the cellular elements of the nephron
(Figure 4a and b); however, the Rb6480 antiserum showed
strong cytoplasmic staining of podocytes (arrows, Figure 4b).
To characterize further the expression of leprecan in specific
glomerular cells, extracts from rat mesangial cells and
immortalized mouse podocytes were electrophoresed and
Western blotted with both polyclonal antisera (Figure 4c). In
podocytes, Rb6480 recognized two bands (arrows at 80 and
100 kDa) in both nonreduced and reduced samples, whereas
Rb2096 recognized the 80 kDa band and, upon reduction,
a prominent 88 kDa (arrowhead) band instead of the larger
10 0kDa band as indicated by Rb6480. In mesangial cells,
a differential pattern of staining on the Western blots
between the two antisera was also seen. Both antisera share
recognition of the 80 kDa band in the nonreduced sample,
but Rb2096 failed to recognize the 100 kDa band. In reduced
mesangial cell extracts, the banding patterns of both
antisera on Western blots are different from those seen in
podocytes.
For comparative purposes, immunohistochemistry on
paraffin-embedded tissue sections from adult rat kidney
was done (Figure 5b) using the new polyclonal antiserum,
Rb6480. Leprecan-associated immunofluorescence was seen
in the mesangial matrix and mesangial cells, Bowman’s
capsule, and tubular basement membranes. Intracellular
staining for leprecan was also noted in podocytes (arrows
and inset), but was noticeably absent from the glomerular
basement membrane. Diffuse immunostaining for leprecan
was also seen in the tubular epithelial cells. The preimmune
antiserum (Figure 5a) showed minimal immunoreactivity
in tissue sections. To confirm further the distribution of
leprecan in adult kidney, tissue sections were probed with a
leprecan antisense riboprobe (Figure 5c–e). Leprecan mRNA
was detected in the renal glomerulus and in the surrounding
tubular epithelium (Figure 5e). Tissue sections incubated
with the sense strand riboprobe showed relatively minimal
label (Figure 5f, g and h) when compared to antisense probe
labeling (Figure 5e).
Leprecan distribution in the early stages of renal
development
Kidney sections from day 1 postnatal animals showed
leprecan-associated immunoreactivity in cells of the outer
cortex (Figure 6a). Leprecan-associated fluorescence was seen
in the developing renal capsule (Figure 6a and b). Early stage
developing glomeruli in the outer cortex showed positive,
albeit weaker, immunoreactivity for leprecan when compared
to the developmentally older glomerular/tubular elements
of the inner cortex. Immunostaining for leprecan was seen
in mesenchymal aggregates (Figure 6b), and comma- and
S-phase glomeruli (Figure 6c). The strongest leprecan
immunoreactivity was seen in tubular epithelial cells in the
inner cortex (Figure 6a and d) and in mesangium/mesangial
cells in maturing glomeruli (Figure 6d). Some, but not all,
areas of Bowman’s capsule (arrows) showed linear immuno-
reactivity for leprecan. The pattern of leprecan mRNA
expression mirrored the former immunohistochemistry
studies. Leprecan mRNA localization was seen throughout
the entire outer cortex, with varying degrees of density
(data not shown). All cells in the mesenchymal aggregate
Treatment group
75 kDa
Rb6480
50 kDa
37 kDa
25 kDa
4 *
3.5
3
2.5
2
1.5
1
0.5
0
R
el
at
ive
 fl
uo
re
sc
en
ce
 u
ni
ts
 (×
 
10
4 )
R
b2
09
6
R
b2
09
6
pr
ei
m
m
u
n
e
preimmune
R
b6
48
0
R
b6
48
0
2n
d 
AB
 C
on
Ba
ck
gr
o
u
n
d
pr
ei
m
m
u
n
e
Figure 2 | A graph of the results of an ELISA that used the peptide
T71ELPWAPDLDLGPASSLNHDPGAAALHD98 as the antigen. Only
the Rb6480 antiserum recognizes the peptide in the ELISA assay, the
preimmune antisera, Rb2096, and the secondary antibody all fail
to give a signal significantly greater than the background signal.
The Western blot adjacent to the graph shows that the antibody
recognizes the sequence contained in the expressed leprecan fusion
protein representing M1-Q399 of the leprecan sequence whereas the
preimmune serum does not.
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stage glomeruli showed even labeling for leprecan mRNA,
(Figure 7j). In comma-phase glomeruli (Figure 7k), leprecan
mRNA expression was strongest in epithelial cells present
in the ‘tail’ of the comma and that ultimately develop into
visceral and parietal epithelial cells and in the cells within
center of the comma. In capillary loop phase glomeruli
(Figure 7l), all cells within that structure were evenly labeled.
Leprecan expression in a model of glomerular hypertrophy
Because of the temporal and spatial pattern of expression of
leprecan in the developing and adult kidney, we wanted to
investigate the potential for changes in the pattern of leprecan
expression in an animal model of glomerular hypertrophy
that developed from a moderate, defined stress to the renal
glomerulus. Archival sections of kidneys from unilateral
nephrectomized rats (2 months duration of nephrectomy)
and sham-operated control animals were immunostaining
using Rb6480 (Figure 8). The pattern of expression of
leprecan in the hypertrophic glomeruli in the unilaterally
nephrectomized animals (Figure 8b) was similar to that seen
in the sham-operated control animals (Figure 8a), with
leprecan-associated immunofluorescence present primarily in
the mesangial matrix and mesangial cells within the glome-
rulus. However, in the case of the hypertrophic kidneys, the
apparent area of leprecan staining in the glomerulus
appeared to be increased, suggesting that during glomerular
hypertrophy there is a compensatory increase in leprecan
synthesis by the mesangial cells.
DISCUSSION
In this study, a new leprecan antiserum was used to examine
the patterns of distribution of leprecan in adult and
developing kidney. In glomeruli from adult animals, leprecan
staining was seen primarily in mesangial cells, mesangial
matrix, podocytes, and Bowman’s capsule. In the remainder
of the kidney, intracellular staining in tubular epithelium was
seen, with some staining in tubular basement membranes.
In the developing kidney, leprecan staining was seen in all
cells of the developing renal cortex, with the strongest
staining seen in the mesangial matrix and mesangial cells, and
in tubules associated with maturing glomeruli.
Vranka et al.6 reported that the distribution of leprecan in
the kidney was limited to the renal capsule but was absent in
renal tubules and glomeruli in the day 16 developing chick.
The conclusion of that study was that outside the renal
capsule, leprecan was not expressed in the kidney. The
conflict between the two observations might be due to a
species-specific spatial pattern of leprecan expression in the
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Figure 3 | The photomicrographs are from a 10-lm-thick frozen
section of adult rat kidney. (a, b) Widefield fluorescent microscopy
images and (c, d) deconvolved images were digitized from
double-label immunostained with monoclonal antibodies directed
against (a, c) a BM-CSPG and (b, d) a polyclonal antiserum (Rb2096)
against leprecan. In previous studies, BM-CSPG was localized to
the mesangial matrix of the glomerulus. Although the widefield
images show overlap of distribution in some areas of the glomerulus
between the two molecules, the deconvolved images better show
that leprecan has both an extracellular and intracellular distribution
in the kidney as indicated by the arrows in (b, d) showing intracellular
staining in a mesangial cell and colocalization in the mesangial
matrix (cf. arrows in a and c). Final magnification  400.
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Figure 4 | Immunohistochemistry and immunoassay for leprecan
using Rb 6480 and Rb 2096. The micrographs are of 10-mm-thick
frozen sections of adult rat kidney immunostained with (a) Rb2096
and (b) Rb6480 antisera. Both images are the result of digital
deconvolution of image stacks of widefield fluorescence images
acquired at 0.1-mm steps. Both antibodies globally stain glomerular
cells, including the parietal epithelial cells of Bowman’s capsule
and the othermost lining fibroblast cells. (b) Rb6480 fluorescence
shows a focal localization in podocytes (arrows), which is not
readily discernable by Rb2096 staining (Final magnfication  400).
(c) The results of a Western blot immunoassay of a 4–12%
SDS-polyacrylamide gel through which mesangial cell or podocyte
cell lysates (NR¼ nonreduced; R¼ reduced) were electrophoresed.
The respective blots are presented as mirror images of one another.
In podocytes, both antisera recognize a 80 kDa band in the
nonreduced (NR) extract lane; Rb6480 also recognizes a second band
at 100 kDa whereas Rb2096 shows minimal, if any immunoreactivity
for the 100 kDa band. In the corresponding reduced (R) lanes Rb6480
gives the same immunoreactivity pattern as in the previous
lane, Rb2096 antiserum recognizes a 90 kDa band. In nonreduced
mesangial cell extracts, both antisera show a banding pattern similar
to that seen in the nonreduced podocyte extract lanes. In reduced
mesangial cell lysates, both Rb6480 and Rb2096 also gave differential
banding patterns, with Rb6480 recognizing 95, 80, and 78 kDa bands
and Rb2096 recognizing a broad band approximately 82 kDa in size.
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avian kidney or, more likely avians utilize another leprecan
family member in the kidney. This probability was first
suggested by the work of Kaul et al.,7 in which leprecan
mRNA in the kidney was absent in a human mRNA Northern
blot but present in a murine mRNA Northern blot. The data
from Jarnum et al.4 showed that the second member of the
leprecan family, leprel1 was present in human kidney. In this
study, we provide data using two polyclonal antisera directed
against distinct regions of leprecan and in situ hybridization
to provide further evidence that leprecan is present in the
stromal elements of the rat kidney during morphogenesis and
development and that its expression in the kidney persists
into adulthood. Our in situ hybridization studies corro-
borate the prior studies of Kaul et al.,7 and show that the
distribution and expression of leprecan mRNA as indicated
by in situ hybridization is relatively homogenous and at low
levels in the adult kidney. However, in renal develop-
ment there are relatively higher levels of leprecan mRNA
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Figure 5 | Leprecan expression in adult glomeruli. The photomicrographs are of (a, b) 4-mm-thick paraffin-embedded sections or (c–h)
10-mm-thick frozen sections of adult rat kidneys. (a, b) The paraffin-embedded sections were immunostained with a polyclonal antiserum
directed against an epitope at the amino end of (b) leprecan (Rb6480) or (a) the preimmune antiserum from the same animal. Leprecan-
associated immunostaining is strong in mesangial cells, the mesangial matrix, and in Bowman’s capsule and weak in tubular basement
membranes. Intracellular staining is evident in the tubular epithelial cells and in podocytes (arrows) associated with the glomerulus. The inset
in (b) shows the intracellular staining for leprecan in an enlarged image of the podocyte that was demarcated by the arrows in (b). The
preimmune antiserum for Rb6480 is essentially nonreactive (a). The micrographs in (c–e) are high magnification (final magnification  400)
of frozen sections of adult rat kidney probed with the antisense RNA probe for leprecan. (c–e) Images of the same field of view taken with
(c) phase-contrast optics, (d) darkfield optics, and (e) a merged image (enlarged) in which the darkfield image has been pseudocolored red. The
silver grains indicative of probe hybridization are evenly dispersed throughout the entire glomerulus. (f–h) Images of rat kidney that were
probed with the sense RNA probe to demonstrate the extent of nonspecific background binding of the probe on the tissue sections.
86 Kidney International (2007) 72, 82–91
o r i g i n a l a r t i c l e M Lauer et al.: Leprecan distribution in the developing and adult kidney
expression, with focal increases in leprecan expression in a
temporal and spatial manner. The mRNA data are further
collaborated by the immunohistochemistry studies. Both
show that in the comma and S-phase structures leprecan
synthesis is initiated and persists in structures that are
actively synthesizing basement membranes.
In the initial characterization of leprecan, we showed that
the parietal endoderm cell line secreted leprecan as a
chondroitin sulfate proteoglycan,2 albeit it was a minor
constituent present in the entire secreted proteoglycan pool.
Since the initial report, the biology of leprecan has become
more complex with the identification of alternative splice
variants of leprecan4,7 and two new family members4 that are
significantly homologous along the entire length of leprecan.
Recent data from human chromosome 1 sequencing efforts9
predict that there are at least three spliciforms of leprecan
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Figure 6 | Rb6480 staining in developing kidney. The photomicrographs are of paraffin-embedded sections of day 1 postnatal rat kidney
immunostained with Rb6480. Low-magnification micrographs of developing kidney show that leprecan was globally expressed throughout
the entire renal parenchyma, but stronger immunofluorescence was found in (b) the renal capsule (arrows) and (a) maturing nephroi (arrows).
(b) In mesenchymal aggregates (indicated by the dashed line), the earliest developmental structures of the nephron, leprecan-associated
immunofluorescence was found in the cytoplasm of the cells composing the aggregates. Cells composing the ureteric bud (ub) also strongly
expressed leprecan. (c) In capillary loop phase glomeruli (indicated by the dashed line), cells of the tail of the comma (arrows) showed
strong, focal staining for leprecan as well as the cells destined to develop into the tubular epithelium. (vc¼ vascular cleft) (d) High
magnification ( 400) of a capillary loop phase glomerulus and its associated tubular elements. The mesangial cells and matrix are strongly
stained by Rb6480, as well as Bowman’s capsule (arrow) and the extraglomerular mesangium (EM). Podocytes are weakly stained by
this antibody and there does not appear to be any staining associated with the glomerular basement membrane. The inset in (d) was
enlarged from the glomerulus shown in the full-view image. (Final magnifications: (a)  200, (b–d)  400.)
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that could occur in humans: leprecan-001 (83 kDa, full
length), leprecan-003 (24 kDa, PH domain lacking), and
leprecan-002 (90 kDa, lacking KDEL signal). The lepre-
can-003 spliciform reported in this database is smaller in size
(219 residues) than the Gros1s (363 residues) spliciform as
reported by Kaul et al.7 Both the long (leprecan-001) and
short (leprecan-003) appear to be expressed in renal tissues.7
Rb6480 would be capable of binding all of the spliciforms,
whereas Rb2096 could bind spliciforms leprecan-001 and
-002 and also leprel1 and leprel2.
In this study, Western blot immunoassay shows that at
least two glomerular cells, podocytes and mesangial cells
make leprecan. The Western blotting assay show the apparent
sizes of the leprecan core protein are slightly different in
podocytes and mesangial cells. Although conceptually
differential core protein sizes could be attained in these cells
by alternative splicing as described above, the observed
differences in core protein sizes in podocytes and mesangial
cells could also be due to post-translational processing
of the resultant core protein in a differential manner (e.g.,
differential n-glycosylation, N-terminus proteolytic proces-
sing). The differential banding patterns between Rb6480
and Rb2096 in Western blot immunoassay of reduced and
nonreduced mesangial cell extracts would suggest this
possibility. However, given the potential cross-reactivity of
Rb2096 with other members of the leprecan family, we
cannot entirely exclude the possibility that glomerular cells
also utilize other leprecan family members.
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Figure 7 | Leprecan expression in developing glomeruli. The photomicrographs were of 10-mm-thick frozen sections of day 1 postnatal rat
kidney that were imaged with (a–c) phase-contrast optics, (d–f) darkfield optics, (g–i) epifluorescence illumination, (j–l) represent the merge of
corresponding darkfield and phase-contrast images. The darkfield images represented as a pseudocolored red overlay over the phase-contrast
image. (d–f) The tissue sections had been probed with antisense leprecan RNA probe and (g–i) counterstained with Hoechst 33242 stain
to highlight the cellular organization of the corresponding structures. (a, d, g, j) Images of a mesenchymal aggregate and surrounding
stromal cells. All cells in the aggregate and the surrounding cells are positive for leprecan expression. (b, e, h, k) Images of a comma-phase
glomerulus, showing localized expression of leprecan in cells of the tail of the comma that will develop into the visceral and parietal epithelium
(arrows). (c) Cells in the center of the comma show enhanced leprecan expression. (vc¼ vascular cleft) (c, f, i, l) Images of an early capillary
loop stage glomerulus, showing high levels of leprecan expression in cells throughout the entire structure. Also note the high levels of
expression in the surrounding stromal tissue. Final magnification  400. Antisense controls for these images are shown in Figure S1.
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We propose that leprecan functions in part as a matri-
cellular protein, its intracellular role in basement membrane-
associated collagen assembly. The temporal and spatial
pattern of expression of leprecan during development and
the observed glomerular response to a hypertrophic stimulus
in preliminary observations would support that premise. In
our earlier studies, the benchmark leprecan protein was
identified as being a chondroitin sulfate proteoglycan made
by L-2 cells. It is likely that the substrates for glycanation
would be the leprecan-002 and -003 splice variants (above),
although previously we were able to show that leprecan
(leprecan-001 splice variant) was also capable of glycanation
and secretion by L-2 cells.2 In this study, we show that
leprecan colocalizes with other proteins present in the
mesangial matrix, suggesting that it may have extracellular
activity. However, the KDEL endoplasmic reticulum retrieval
signal10 indicate a role in cellular secretory pathways. Aravind
and Koonin5 predicted via protein fold recognition algo-
rithms that the carboxyl terminus of leprecan had potential
catalytic activity due to the presence of a 2-oxoglutarate-
Fe(II) fold. Jarnum et al.4 subsequently identified the pre-
sence of a prolyl 4-hydroxylase domain in leprel1, the second
member of the leprecan family. Vranka et al.6 provided
additional compelling evidence that the carboxyl-terminus
domain of leprecan had P3H activity on denatured collagen
and proposed that the P3H activity of leprecan was
important in the assembly of fibrillar collagens. However,
based on the localization patterns in their report (see above),
they deferred assigning this role to the assembly of types IV
and V collagen, which have been previously shown to
contain the largest amounts of 3-hydroxyproline11,12 in the
collagen family. Interestingly, Tryggvason et al.13 demon-
strated a pattern of temporal and spatial expression of P3H
activity that mirrors in part our observations seen with the
expression of leprecan mRNA and protein. It is likely that
the central aspect of leprecan biology is the inherent P3H
activity present in the leprecan-001 and -003 splice variants,
but leaves the biology of the leprecan-002 splice variant and
the regulation of leprecan expression for future investigation.
MATERIALS AND METHODS
Animals and animal care
Animals used in the study were Sprague–Dawley rats from Charles
River Laboratories (Raliegh, NC, USA). Day 1 postnatal pups were
used for the renal developmental studies. Male rats (200 g) were
used to examine the distribution of leprecan in adult animals. The
animals were housed in the Animal Facilities at LSU Health Sciences
Center under conditions of constant temperature and controlled
lighting. Archival tissue sections from kidneys of unilateral
nephrectomized adult male rats (2 months duration, five animals
per group) and sham surgery control animals were used in
preliminary studies to investigate changes in the leprecan distribu-
tion in an animal model of glomerular hypertrophy.
Antibodies
The characterization of polyclonal antiserum Rb2096 directed
against the R403-L728 (Figure 1a) of leprecan was described
previously.2 Identification of a region of leprecan unique from
other leprecan family members, T71-D98 (TELPWAPDLDLG-
PASSLNHDPGAAALHD, Figure 1b), was done using MacVector
(Accelrys, San Diego, CA, USA). A peptide representing this
sequence was synthesized (Open Biosystems, Huntsville, AL, USA)
and used to immunize rabbits for polyclonal antiserum production
as described previously.2
The activity of the polyclonal antiserum, Rb6480, was charac-
terized by Western blot immunoassay and ELISA. For Western
blotting, a fusion protein representing M1-Q399 of leprecan was
expressed in bacteria using the expression vector pDEST24
(Invitrogen, Carlsbad, CA, USA) and purified by nickel-nitrilotria-
cetic acid affinity resin according to the manufacturer’s instructions.
Recombinant protein (35mg) was electrophoresed on a 4–15%
SDS–polyacrylamide gel (Invitrogen) and the proteins electro-
phoretically transferred to nitrocellulose (Osmonics/General
Electric, Trevose, PA, USA) and the blots probed with antibodies
as described previously.2 ELISA was done using the above peptide as
a target and probed with preimmune antisera, Rb2096 and Rb6480.
Cell culture
Mesangial cells (passage 8) were isolated from adult rat kidneys
as described previously.14 Immortalized podocytes15 were isolated
from adult immortomouse (H2Kb-tsA58 mice, Charles River)
kidneys using the method described by Takemoto et al.16 with
a b
Figure 8 | Leprecan expression in hypertrophic glomeruli. The photomicrographs are paraffin-embedded sections of (a) normal adult
rat kidney or (b) unilateral nephrectomized kidney immunostained with Rb6480. Leprecan staining is present in the mesangial matrix/
mesangial cells and Bowman’s capsule in glomeruli from both animals. Staining is also present in the tubular epithelium of both specimens.
In the case of the glomerular hypertrophy seen in (b) the unilateral nephrectomized animal there is an apparent increase in the area of
leprecan staining compared to the normal animal. Final magnification  400.
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minor modifications.Podocyte cell lines were developed from cells
that were characterized as nestinþ ,17 WT-1þ 15 by immuno-
histochemistry (Santa Cruz Biotechnology, Santa Cruz, CA) (see
Figure S2). Cells were extracted in Laemmli buffer and SDS–PAGE
and Western blotting done as described previously.2
Tissue harvest and processing
For immunohistochemical studies, kidneys were removed from
animals euthanized with isoflurane (Halocarbon Inc., River Edge, NJ,
USA) and fixed in 100% ethanol for paraffin embedding, or
snap-frozen in OCT compound and subsequently embedded in the
same medium. For in situ hybridization studies, kidneys from adult
animals were fixed by perfusion fixation in 4% paraformaldehyde in
phosphate-buffered saline prepared with diethypyrocarbonate
(DEPC)-treated water and held in the same fixative overnight.
Kidneys from postnatal animals were fixed by immersion fixation in
4% paraformaldehyde in phosphate-buffered saline. Afterwards the
kidneys were sunk/infiltrated overnight at room temperature in 30%
sucrose in DEPC-treated water. The tissues were then embedded by
snap freezing in OCT compound in prechilled metal molds then
stored at 801C. Paraffin processing of tissues was done as described
previously.18 Paraffin sections were cut at 4-mm thickness using a
rotary microtome. Frozen sections were cut at 10 mm using a
refrigerated microtome.
In situ hybridization
For in situ hybridization, stored slides were equilibrated to room
temperature then warmed at 501C for 15 min. An in situ
hybridization kit, mRNAlocator, (Ambion, Austin TX, USA) was
used for the studies. For hybridization, the slides were rinsed with
1 phosphate-buffered saline in DEPC-treated water (3 5 min)
while gently agitated on an orbital shaker. Slides were then
incubated in 1.32% triethanolamine in DEPC water for 3 min at
room temperature with gentle agitation, then incubated in 1.32%
triethanolamine in DEPC water, with acetic anhydride for 10 min, at
room temperature with gentle agitation. Slides were rinsed in
1 phosphate-buffered saline for 5 min at room tempera-
ture with gentle agitation. The slides were prehybridized at 571C
for 2 h in a moist chamber. Hybridization (probe-specific activity
50 000 c.p.m./ml, total volume 100ml per slide) was done overnight
at 571C. Afterwards the slides were washed at 571C in the following
buffers: 4 SSC/1 mM dithiothreitol for 5 min; 2 SSC/1 mM
dithiothreitol for 30 min; RNAse A treatment for 30 min at 371C;
2 SSC/1 mM dithiothreitol for 30 min; and 0.1 SSC for 30 min.
The slides were then dehydrated in a graded series of ethanol then
allowed to air dry for 1 h. The slides were coated with NTB
autoradiographic emulsion (Kodak, Rochester, NY, USA) and stored
following manufacturer’s directions. Sets of slides were developed at
2- and 4-week intervals according to the manufacturer’s instruc-
tions and counterstained with toluidine blue. Hoechst 33242 stain
(Invitrogen) was used as a nuclear counterstain at a 1:1000 dilution
in water followed by 3 2 min rinses in water. The slides were
coverslipped with aqueous mounting medium.
cDNA and single stranded RNA probe preparation
A 181 bp (1420–1600) region of leprecan was amplified from a
plasmid containing a full-length leprecan construct by PCR using a
forward primer 50-GATCTCTGATGACGAGTGCCAGGAACTGCA-30
and reverse primer 50-CATGTGGGCGCTCTGCAGAGGAACTTTC-
30, the sequence spanning exons 9–11 of the leprecan gene (Figure 1c).
The resultant product was cloned into the PCR4 blunt TOPO vector
(Invitrogen) and propagated by transformation into Top10 cells
(Invitrogen) grown on LB agar plates supplemented with 50mg/ml
kanamycin. For isolating plasmid DNA, an Eppendorf Plasmid
Isolation kit was used according to the manufacturer’s instructions.
Confirmation of the identity of the insert was done by DNA cycle
sequencing using M13 forward and M13 reverse primers.
To generate sense and antisense RNA probes, 3.0 mg of DNA
template was linearized in separate restriction enzyme digests with
SpeI or NotI (Promega, Madison, WI, USA) following manu-
facturer’s protocol. The linearized DNA was additionally treated
with 0.5 M EDTA, 200 mg/ml proteinase K, and 0.5% SDS and
incubated at 501C for 30 min. Afterwards, the DNA was extracted
twice with phenol chloroform isoamyl and subsequently extracted
twice with chloroform. To aid in phase separation, 400 ml of phase
lock medium (Eppendorf, Westbury, NY, USA) was used during the
extraction protocol. The DNA was precipitated with Pellet Paint Co-
precipitant (Novagen, EMD Sciences, Madison, WI, USA) according
to manufacturer’s instructions and resuspended in 5 ml of 10 mM
Tris, 0.1 mM EDTA, and stored at 201C. An aliquot of the DNA was
electrophoresed on a 1% agarose (BioRad, Hercules, CA, USA) gel
in 1TAE buffer to verify linearization and to quantify DNA.
For 33P labeling, linearized cDNA was reverse-transcribed using
MAXIscript In Vitro Transcription Kit (Ambion, Austin, TX, USA)
according to the manufacturer’s instructions. To verify full-length
transcripts, a 1 ml aliquot of each probe prepared was electro-
phoresed on a 5%acrylamide, urea, and TBE gel (BioRad). After-
wards, the gel was exposed to BioMax MR film (Kodak) for 15 min,
the resultant radiograph developed in an X-ray film processor.
Immunohistochemistry
Single- and double-label immunohistochemistry were done on
frozen and paraffin sections as described previously.2,19 Some
sections were counterstained with Hoechst 33242 nuclear stain
(Invitrogen) at 1:1000 dilution. Controls for immunostaining
consisted of slides where the preimmune antiserum was used in
place of the respective primary antiserum in the case of the
polyclonal antiserum. In the case of monoclonal antibodies, a
nonimmune mouse immunoglobulin of the same isotype as the
monoclonal antibody probe was used. Cy2- and Cy3-labeled species-
specific secondary antibodies (donkey anti-mouse IgG, donkey
anti-rabbit IgG) were purchased from Jackson Immunoresearch
(Malvern, PA, USA).
Microscopy
Slides were imaged using an Olympus IX-70 inverted microscope
equipped for epifluorescent illumination or a Leica Ortholux
microscope equipped for phase-contrast, darkfield, and epifluor-
escent illumination. Images of tissue sections were digitized using a
Hammatsu OrcaTM digital camera (Hammatsu, CT, USA) or a Sensys
digital camera (Roper Instruments, Tuscon, AZ, USA), the signal
from which was ported to a Macintosh G4 computer hosting the
imaging software IPLabSpectrum (Scanalytics BD Biosciences,
Rockville, MD, USA). The digital deconvolution software Micro-
tomeTM (Vaytek Inc. Iowa City, IA, USA) was used to enhance the
resolution of staining in 10-mm-thick frozen sections, using a nearest
neighbor deconvolution algorithm on acquired z-stepped (0.1 mm
step) images. For in situ hybridization, slides were imaged using a
darkfield condenser and the image pseudocolored red to enhance
the contrast of the grains on the phase-contrast images. Image
alignment with the phase-contrast image was done using IPLab-
Spectrum.
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SUPPLEMENTARY MATERIAL
Figure S1. The plate is a composite of the in situ hybridization images
presented in Figure 7 with the corresponding sense strand mRNA
probe hybridization images.
Figure S2. Glomerular isolation was done using the protocol of
Takemoto et al.1 with minor modifications.
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